Managing antibiotics wisely in a neonatal intensive care unit in a low resource setting

J. M. Graus1,2, C. Herbozo1,2✉, R. Hernandez1,2, A. F. Pantoja1,3 and J. Zegarra1,2

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022

INTRODUCTION
Antibiotics are the most commonly prescribed medication in the neonatal intensive care unit (NICU) [1–4]. Treatment with antimicrobials might be life-saving in cases with bacterial infection, nonetheless, antibiotic overuse can be detrimental. It may condition adverse patient outcomes, and pose a threat to the NICU as well as a public health problem, due to the emergence of multidrug resistant organisms, especially when there is antibiotic overuse in the community [5, 6].

Early antibiotic exposure might disrupt the developing neonatal gut microbiome and may cause substantial changes in the developing microbiota [7–9]. Prolonged use of antibiotics has been associated with increased mortality, major morbidities such as late onset sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and neurodevelopment impairment in very low birth weight (VLBW) infants [10–19]. Other consequences related to antibiotic overuse include an increase in antimicrobial resistance and the appearance of fungal infections, as well as higher health care costs. The emergence of multidrug resistance bacteria not only affects each unit, but also society as a whole [20, 21]. Antibiotic exposure also presents long term consequences. It has been associated with an increase in wheezing, atopic and allergic disorders, bowel inflammatory disease as well as childhood obesity [22–25].

Antibiotic use varies widely among different NICUs [26]. Even in the absence of a positive culture to prove infection, many physicians continue to treat patients with a presumptive diagnosis of “culture-negative sepsis”, resulting in unnecessary overuse of antibiotics [4, 27].

Antibiotic stewardship programs (ASP) have been successful in decreasing inappropriate use of antibiotics in NICUs. In a point prevalence study in 84 NICUs in 29 countries, Prusakov et al. [26] showed that NICUs with ASPs had significantly lower rates of antibiotic use compared to NICUs without ASPs.

In the last decade, there have been various international campaigns addressing the need of antibiotic stewardship in order to rationalize and safely reduce the use of antibiotics [28]. In 2014, the Center for Disease Control and Prevention (CDC) presented the 7 core elements for antibiotic stewardship, which was updated recently [29]. Starting in 2015, the Vermont Oxford Network partnered with the CDC in a collaborative effort, “Choosing antibiotics wisely” and successfully reduced the misuse of antibiotics in NICUs that voluntarily enrolled in the collaborative [30].

In this study, we show our experience developing a quality improvement (QI) initiative to rationalize and reduce the use of antibiotics in a level 3 neonatal unit in a middle income country, through the introduction of an antibiotic stewardship program.

METHODS
Setting
This single-center quality improvement (QI) project was conducted in a 25-bed level 3 NICU in Lima, Peru, at Hospital Cayetano Heredia. This NICU has nearly 500 admissions per year and approximately 75 VLBW infants per year. Our Hospital has all pediatric subspecialties and pediatric surgery. Only patients with congenital heart disease or neurological conditions that require surgery are transferred to a level 4 referral center.

Ethical Considerations: Our Institutional Review Board determined that this study qualified as a QI project therefore did not require its oversight.

1University Peruana Cayetano Heredia, School of Medicine, Lima, Peru. 2Hospital Cayetano Heredia, Lima, Peru. 3St Joseph Hospital, Denver, CO, United States.

✉email: Cecilia.herbozo.n@upch.pe

Received: 24 August 2021 Revised: 17 March 2022 Accepted: 31 March 2022
Published online: 22 April 2022
Fig. 1  Key driver diagram.

Program design
The design of this project began in May 2018. A multidisciplinary team was formed, which included neonatologists, neonatology fellows, a pediatric infectious diseases physician, NICU registered nurses and microbiology laboratory technicians. It was established as the Neonatal Infections Committee. Our team did not include a pharmacist since we do not have a pharmacist assigned to our Unit. Our project had support from the NICU director, the department of Epidemiology and the Hospital Medical Direction. Participation was voluntary and there was no funding for this program. Members of the committee had no conflict of interest in relation to this program.

Education sessions were held weekly in order to complete training on principles of antibiotic stewardship and quality improvement.

The team reviewed baseline data and designed a key driver diagram (Fig. 1), which served as a guide for project implementation and to organize our approach to reduce antibiotic use in the NICU. Our primary drivers were: team development, education, culture change, regular reporting of antibiotic use.

Intervention
The project began in July 2018. Baseline data of antibiotic usage rate (AUR) was obtained in July and August 2018. AUR was defined as the total number of days that infants were exposed to antibacterial agents, given intravenously or intramuscularly, divided by 1000 patient-days [31].

Over the next 24 months, we sequentially implemented seven Plan-Do-Study-Act (PDSA) cycles following the model of improvement [32].

PDSA 1: Blood culture collection standardization and reporting
In August 2018, blood culture sampling was standardized in the NICU, with a volume of at least 1 ml drawn for every blood culture. Staff were reeducated on the desired blood volume for cultures. A registry was created to gather data from all blood, urine, cerebrospinal fluid cultures in a standardized manner. There was a mandatory field created to document blood volume drawn for cultures, so that all health providers knew how much volume had been obtained. Also, daily communication was established with the microbiology laboratory, which allowed for a timely information regarding culture results.

PDSA 2: Optimal use of antibiotics
On September 2018, education sessions were held with NICU personnel in order to disseminate guidelines of antibiotic optimal use. Education sessions included discussion of cases, capacity development in prevention and management of infections, training in adequate antibiotic prescription and rationale for stewardship. The standard empiric antibiotic regime for an infant with a suspected diagnosis of early-onset sepsis (EOS) in our NICU is ampicillin and gentamicin. For babies with suspected EOS with meningitis, ampicillin and cefotaxime.

PDSA 3: Discontinuation of antibiotics at 48 h
Since our hospital does not have an electronic medical record, starting in October 2018, two neonatologists (J.Z and J.G), members of the team, standardized a routine daily communication with the microbiology laboratory to check the results of the blood cultures of patients in the NICU in order to establish a timeout for antibiotic use. The results were then communicated to the attending neonatologist. This prompted a discussion with the health care team to decide whether antibiotics should be discontinued if the blood culture was negative by 48 h. If the decision was to continue antibiotics, entertaining the diagnosis of “culture negative sepsis”, the rationale for that decision was documented in the medical record. With positive culture results, the team selected an appropriate antibiotic coverage.

PDSA 4: Monthly monitoring and review of AUR
On January 2019, monthly meetings were started in order to review data of AUR and discuss further change ideas. Information regarding AUR and its monthly tendency was posted in a main location in the entrance to the NICU in order to provide a visual display of changes occurring overtime.

PDSA 5: Education for new residents and fellows
On July 2019 and July 2020 new residents and fellows were incorporated in our department, so educational sessions on neonatal sepsis, optimal antibiotic use and antibiotic stewardship were held.

PDSA 6: Evidence based medicine (EBM) journal club meetings
On November 2019, a weekly EBM journal club was started in order to review current evidence regarding the best approach to infants born to mothers with intrauterine infection, the approach to EOS, the use of biomarkers for the diagnosis of sepsis, etc.

PDSA 7: Introduction of the observational method for diagnosis of EOS
On August 2020 our clinical practice guideline (CPG) for EOS was updated. We introduced the observational method for diagnosis of EOS. With the new CPG, newborns with risk factors are observed and are screened a structured physical examination is done every 6 h in order to be able to identify any clinical symptoms or signs of infection. No antibiotics are started unless the infant presents with signs or symptoms suggesting sepsis. This CPG excluded extremely low birth weight infants. One of the aims of this CPG was to reduce antibiotic use in preterm infants and to avoid treating the healthy appearing term or near term newborn with a maternal diagnosis of chorioamnionitis. We standardized which clinical signs and laboratory findings would be taken into consideration in order to diagnose culture-negative sepsis. The duration of antibiotic treatment for confirmed sepsis was standardized according to the causal microorganism. Treatment for culture-negative sepsis was standardized to 7 days.

Table 1 shows the timeline of the interventions.

Measures
The primary outcome measure was the AUR. Antibiotic data was obtained from a manual review of the medical charts done on a daily basis and NICU patient-days were obtained from the hospital daily census. Throughout the implementation of our interventions, we registered all EOS cases and readmissions of newborns after discharge as a safety measure.

Ethical considerations
This project is a quality improvement project; therefore it was considered exempt from ethical approval and consent process.

RESULTS
During the period of time studied, between July 2018 and December 2020, there were 12051 births at Hospital Cayetano
Heredia. 858 newborns were admitted to our NICU (7.1% of live births). 325 newborns (37.9% of infants admitted) were admitted with a rule/out EOS diagnosis. There were 15 cases of EOS (0.2% of newborns). 325 newborns (37.9% of infants admitted) were admitted for suspected EOS.

Baseline data of antibiotic use was gathered in July and August 2018 with an AUR of 291 and 335/1000 patient days respectively. Our initial aim was to diminish AUR in 20%. Baseline and ongoing AUR values were plotted in a Statistical Process Control Chart (SPCC) (Fig. 2). The first significant drop in AUR occurred after successful implementation of the first 3 PDSA cycles. When antibiotic time-out was established at 48 h, there was a continued drop in AUR. Monthly monitoring and review of AUR also prompted a further decrease of AUR, reaching a total decrease of 65.1% from baseline. (Fig.2).

In November 2019, a weekly EBM journal club was established in order to update our CPG on EOS. In August 2020, we started following the updated CPG for EOS (PDSA cycle 7) which furthered the decrease of AUR, reaching a total decrease of 65.1% from baseline. (Fig. 2).

Figure 3 shows a Statistical Process Control Chart (SPCC), p-chart displaying the use of empirical antibiotic therapy in VLBW infants. Initially, there was a great variability in the use of empirical antibiotic therapy in these infants, with a mean of 78.8% of VLBW infants receiving antibiotics empirically since birth. In June 2020, a downward shift in the use of empirical antibiotics was noted, which became greater after August 2020, after successful implementation of the new CPG for EOS, with a mean of 44.4% of VLBW infants receiving empirical antibiotic therapy. This represents a relative decrease of 43.7%. As seen in Fig. 3, use of antibiotics continued to decrease in the following months.

Figure 4 shows a p-chart displaying the percent of infants discharged each month without ever receiving antibiotics. After implementing our QI project we noticed an increase in the number of patients who were admitted in the NICU and were discharged without ever receiving antibiotics to 64.3%. There was no increase in the cases of EOS following the antibiotic discontinuation nor infants readmitted for sepsis after discharge, nor mortality.

DISCUSSION

Our study describes a comprehensive, sequential approach conducted in a level 3 NICU in Peru that safely decreased unnecessary antibiotic use in our NICU. Our multidisciplinary team applied core QI principles, and through a sequential approach we were able to lower the AUR by 65.1% over a 30 month period, through the establishment of 4 primary drivers: team development, education, culture change and regular reporting of antibiotic use to all NICU personnel. We exceeded our initial project’s aim which was to diminish AUR by 20%. In the first 9 months, we accomplished a decrease of 57% in AUR, and this decrease was sustained and even surpassed in the following 19 months.

We believe the interventions we have described in our study can be easily replicated in other centers and therefore are likely to be of interest for neonatologists in middle income countries such as ours. An interesting aspect is that two members of the team communicated blood culture results to the attending physicians every day of the week, which shows that units without EMRs can achieve judicious antibiotic use in settings with low resources. Recent antibiotic stewardship QI projects published in the literature, such as Meyers et al. [33] in the USA or Makri et al. [34] in UK developed in high resource settings showed similar or more modest success. Our project, despite being developed in a hospital with limited resources, was able to demonstrate a successful approach to safely diminish antibiotic use in our patients, an approach that could be applicable to most, if not all NICUs. There was no increase in the cases of EOS following the antibiotic discontinuation nor infants readmitted for sepsis after discharge, nor mortality.

We believe the decline in the AUR was mostly due to the sequential implementation of the planned interventions, particularly the first 4 interventions: standardizing blood culture sampling, education in terms of judicious antibiotic use, the 48 h “time-out” in antibiotic orders, which prompted a discussion with the treating team about the recommended best practice to discontinue antibiotics if culture was negative, and monthly monitoring and regular reporting of AUR. As mentioned earlier, the order to discontinue antibiotics if the cultures were negative had to be hand written in the baby’s medical chart. The definition

| Table 1. Timeline of interventions. |
|-------------------------------------|
| **Date**   | **Description of intervention** |
| August 2018 | Blood culture collection standardization |
| September 2018 | Dissemination of guidelines of optimal use of antibiotics |
| October 2018 | Discontinuation of antibiotics at 48 h |
| January 2019 | Monthly monitoring and review of AUR |
| July 2019 | Education for new residents and fellows |
| November 2019 | Evidence based journal club meetings |
| July 2020 | Education for new residents and fellows |
| August 2020 | Introduction of the updated CPG for diagnosis of early-onset sepsis |

| Table 2. Demographic characteristics. |
|--------------------------------------|
| **Demographic characteristics** | **Total (%)** |
| **Total number of births** | 12051 |
| **Newborns admitted to the NICU** | 858 (7.1%) |
| **Suspected EOS episodes** | 325 (37.9%) |
| **EOS episodes with positive culture** | 15 (4.6%) |
| **Culture negative EOS** | 128 (39.4%) |
| **Ruled out EOS** | 182 (56%) |
| **Male** | 168 (51.7%) |
| **Female** | 157 (48.3%) |
| **Gestational age (weeks)** | **Total (%)** |
| <25 | 12 (3.7%) |
| 25–30 | 115 (35.4%) |
| 31–35 | 109 (33.5%) |
| 36–40 | 80 (24.6%) |
| >40 | 9 (2.8%) |
| **Weight (grams)** | **Total (%)** |
| <500 | 3 (1%) |
| 500–999 | 55 (17%) |
| 1000–1499 | 76 (23%) |
| 1500–1999 | 57 (18%) |
| 2000–2499 | 46 (14%) |
| >2500 | 88 (27%) |
of culture negative sepsis is very challenging and before this study, there was some mistrust in blood cultures in our hospital, given that some practitioners believed that their sensitivity was extremely low. To believe in the results of a negative blood culture in the context of a baby showing clinical improvement, represented a significant change in our culture. Initially this was done at 48 h, but after 1 year, we decided to discontinue antibiotics at 36 h, given our own experience and the strong evidence of the literature showing that bacterial growth in blood cultures occurs in the initial 24 to 36 h [35, 36]. Also, regular reporting and visual display of changes in AUR in the “quality board” of our Unit, starting in January 2019 (PDSA cycle 4) prompted a further decrease in AUR. We believe visual display was important, given that it gives continued feedback to our team and all NICU health care givers, and helps achieve a culture change, which we believe was instrumental to achieving and sustaining our goal. We also believe that the evidence-based journal club started in November 2019, facilitated compliance of neonatologists to our initiative given that they were made part of the decision making process for the development of the CPG.

Even though there was a sustained decrease in AUR between September 2018 and June 2019, there was a spike in the AUR in February 2019, as noted in Fig. 2. This coincided with an outbreak of extended-spectrum-beta-lactamase organisms in our unit which caused late onset sepsis, in the context of an increase in our average daily census (overcrowded unit), which also led to an increase in mortality in our population. In this context, physicians were reluctant to discontinue antibiotics given the high rate of mortality attributable to these infections at that point.

There was also an increase in AUR in July 2019. It is important to consider that the presence of new personnel, such as new residents and fellows working in the NICU, could compromise the achievements reached; therefore it is recommended to assure adequate training and sufficient supervision.

Figure 2 also shows that in spite of the COVID-19 pandemic which started in March 2020 in our country, the decrease in AUR continued to decrease over the following months, revealing that this world-wide health emergency did not have an effect on our QI project, even though we had a higher census in our Unit given the admission of babies born to mothers with COVID-19.
CONCLUSIONS

Through a quality improvement initiative encompassing a comprehensive approach that included team development, education, culture change and regular reporting of antibiotic use, we were able to lower the antibiotic usage rate by 65.1%. We safely and successfully reduced unnecessary antibiotic use. We believe all NICUs should address antibiotic stewardship as it can be successfully achieved even in low resource settings such as ours.

REFERENCES

1. Hsieh EM, Homik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB. Best pharmaceuticals for children act- pediatric trials network. medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31:811–21.
2. Grohskopf LA, Huskins WC, Sinkowitz-Cochran RL, Levine GL, Goldmann DA, Jarvis WR. Pediatric prevention network. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J. 2005;24:766–73.
3. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117:1979–1987.
4. Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135:826–33.
5. de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355:973–8.
6. Johnston KJ, Thorpe KE, Jacob JT, Murphy DJ. The incremental cost of infections associated with multidrug-resistant organisms in the hospital setting. A national estimate. Health Serv Res. 2019;54:782–92.
7. Azad MB, Konya T, Persaud RR, Guttmann DS, Chari RS, Field CJ, et al. CHild Study Investigators. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG. 2016;123:983–93.
8. Nogacka A, Salazar N, Suárez M, Milani C, Arboleya S, Solís G, et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome. 2017;5:93.
9. Stearns JC, Simioni J, Gunn E, McDonald H, Holloway AC, Thabane L, et al. Intrapartum antibiotics for GBS prophylaxis alter colonization patterns in the infant gut microbiome of low risk infants. Sci Rep. 2017;7:16527.
10. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NL, Sanchez PJ, et al. NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123:38–66.
11. Puopolo KM, Mukhopadhyay S, Hansen NL, Cotten CM, Stoll B, Sanchez PJ, et al. NICHD Neonatal Research Network. Identification of extremely premature infants at low risk for early-onset sepsis. Pediatrics. 2017;140:e201711600.
12. Ting JY, Synnes A, Roberts A, Deshpande A, Dow K, Yoon EW, et al. Canadian Neonatal Network Investigators. Association between antibiotic use and neonatal mortality and morbidity in very low birth-weight infants without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr. 2016;170:1181–7.
13. Novitsky A, Tuttle D, Locke RG, Saiman L, Mackley A, Paul DA. Prolonged early antibiotic use and bronchopulmonary dysplasia in very low birth weight infants. Am J Perinatol. 2015;32:43–8.
14. Ting JY, Roberts A, Sherlock R, Ojah C, Cieslak Z, Dunn M, et al. Duration of initial empirical antibiotic therapy and outcomes in very low birth weight infants. Pediatrics. 2019;143:e20182286.
15. Ting JY, Synnes A, Roberts A, Deshpande A, Dow K, Yang J, et al. Association of antibiotic utilization and neurodevelopmental outcomes among extremely low gestational age neonates without proven sepsis or necrotizing enterocolitis. Am J Perinatol. 2018;35:972–8.
16. Canyeb J, Huffman LW, Subramanian A, Marshall AS, Ballard AR, Lefevre C, et al. Antibiotic exposure and risk for death or bronchopulmonary dysplasia in very low birth weight infants. J Pediatr. 2017;181:289–93.
17. Alexander V, Northrup V, Bizarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr. 2011;159:392–7.
18. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011;159:720–5.
Cantey JB, Pyle AK, Wozniak PS, Hyman LS, Sánchez PJ. Early antibiotic exposure and adverse outcomes in preterm, very low birth weight infants. J Pediatr. 2018;203:62–7.

Cantey JB, Millstone AM. Bloodstream infections: epidemiology and resistance. Clin Perinatol. 2015;42:1–16.

Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717–22.

Kummeling I, Stelma FF, Dagnelie PC, Snijders BE, Penders J, Huber M, et al. Early antibiotic exposure and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOLALA Birth Cohort Study. Pediatrics. 2007;119. Available at: www.pediatrics.org/cgi/content/full/119/1/e225.

Metsälä J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Mother’s and offspring’s use of antibiotics and infant allergy to cow’s milk. Epidemiology. 2013;24:303–9.

Prusakov P, Goff DA, Wozniak PS, Cassim A, Scipion CEA, Urzúa S, et al. For the MAS-R study. EClinicalMedicine. 202132:100727. https://doi.org/10.1016/j.eclinm.2021.100727. PMID: 33554094; PMCID: PMC7848759.

Schulman J, Profit J, Lee HC, Dueñas G, Bennet MV, Parucha J, et al. Variations in neonatal antibiotic use. Pediatrics. 2018;142:e20180115.

World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva, Switzerland: World Health Organization; 2015.

Puopolo KM, Benitz WE, Zaoutis TE. AAP COMMITTEE ON FETUS AND NEWBORN, AAP COMMITTEE ON INFECTIOUS DISEASES. Management of neonates born at ≤34 6/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis. Pediatrics. 2018;142:e20182896.

ACKNOWLEDGEMENTS
We would like to thank Katherine Amaro, Stephanie Andrade and Ely Salazar for their continued help in the microbiology laboratory.

AUTHOR CONTRIBUTIONS
JMG conceptualized and designed the study, designed the data collection instrument, collected data, carried out the analyses and reviewed and revised the manuscript. CH collected data, carried out the analyses, drafted the initial manuscript and reviewed and revised the manuscript. RH and AFP carried out the analyses and reviewed and revised the manuscript. JZ conceptualized and designed the study, collected data and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Cecilia Herbozo.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.